OBJECTIVES: To compare the cost-effectiveness and cost-utility of a new orphan drug trabectedin, Yondelis, against various end-stage treatments (EST) following the failure with two chemotherapy agents (anthracycline and ifosfamide) that are approved for the first line treatment of mSTS in Finland. METHODS: An Excel-based Markov model with trabectedin and no trabectedin arms is used in the evaluation. Analyses are performed from a societal lifetime perspective (production losses and VAT excluded) using a probabilistic (second-order Monte Carlo) approach. The costeffectiveness is evaluated on the basis of cost-effectiveness acceptability frontier, incremental cost per life-year gained (LYG) and quality-adjusted life-years (QALY) gained. Included resources are drugs, mSTS treatments, adverse event treatments and travelling. In the base case analysis, 33% of patients are assumed to receive EST (67% etoposide, 33% dacarbazine). The effectiveness of drugs is based on the indirect comparison of EORTC Soft Tissue and Bone Sarcoma Group (Nielsen 2000; van EORTC Soft Tissue and Bone Sarcoma Group (Nielsen 2000; van Oosterom 2002) and ET743-STS-201 trial results. Finnish resources and costs from ET743-STS-201 trial results. Finnish resources and costs from year 2006 are taken, and both costs and outcomes are discounted with 5% per annum. RESULTS: Trabectedin is associated with incremental 1.14 LYGs, a37,875 additional costs and a33,099 cost per LYG compared to EST. With the willingness to pay of a50,000 per LYG, trabectedin has over 98% probability of being cost-effective. When the quality of remaining life time is taken into account using assumptions, the incremental cost per QALY range between a38,801-a46,425. The results are robust according to multiple sensitivity analyses (including also comparisons against other ESTs: etoposide or dacarbazine monotherapy; doxorubicin, ifosfamide, mesna and dacarbazine (IADIC); ifosfamide, mesna, etoposide, fenobarbital and growth hormone (IE); and ifosfamide, mesna, etoposide and methotrexate (IMVP-a6)). CONCLU-SIONS: Trabectedin is a valuable addition for the treatment of mSTS. The costeffectiveness of trabectedin is comparable or even superior to many other cancer drugs for non-orphan conditions.
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Queensland Institute of Medical Research, Brisbane, Australia, 2 Auckland Hospital, Auckland, New Zealand, 3 The University of Auckland, Auckland, New Zealand OBJECTIVES: Several genetic characteristics are implicated in the onset of lung cancer and the smoking-gene interaction means that some smokers are at greater risk of developing lung cancer than others. The purpose of this study was to explore the potential cost-effectiveness of offering smokers a genetic test designed to provide feedback regarding their individual risk of developing lung cancer to motivate smoking cessation. METHODS: Two strategies were modelled; heavy-smoking individuals aged 50 years either received or did not receive a genetic test within the course of a usual smoking-cessation intervention comprising nicotine replacement therapy (NRT) and counselling. A Markov model was constructed using evidence from published randomized controlled trials and meta-analyses for estimates on 12-month quit rates and long-term relapse rates. Recent epidemiological data were used for estimates on the risk of developing lung cancer stratified by time since quitting and heavy/light smoking patterns. Scenario analyses, one-way and probabilistic sensitivity analyses were used to explore uncertainty. RESULTS: The discounted incremental costs for the genetic testing strategy were AU$299 and corresponding quality-adjusted life years (QALYs) were 0.0109 producing an incremental cost per QALY of AUS$34, 687 (95% CI $12, 483, $87, 734) . At a willingness-to-pay of AU$20,000 per QALY gained, the genetic testing strategy needs to have a minimum 12-month quit rate of 12.4% or the relapse rate 12% lower to demonstrate cost-effective equivalence to NRT and counselling alone. The probability that adding a genetic test to the usual smoking-cessation intervention is cost-effective was 20.6%. CONCLUSIONS: Very small differences in costs and QALYs were found between the two options over a period of 35 years. The findings were sensitive to small changes in critical variables such as the 12-month quit rates and relapse rates. Further research on smoking-cessation quit rates following genetic testing is needed to inform cost-utility analyses.
PCN107 107 COST-EFFECTIVENESS OF HPV VACCINATION-AN OVERVIEW ON INTERNATIONAL STUDY RESULTS
Damm O, Greiner W University of Bielefeld, Bielefeld, Germany OBJECTIVES: In multiple clinical trails the efficacy of HPV vaccination against virus-specific pre-stages of cervical cancer was verified. Because decision-makers are increasingly interested in information on the cost-value ratios of new interventions we conducted a systematic review to summarize current international evidence concerning the long-term cost-effectiveness of HPV vaccination. METHODS: To ascertain studies published in the peer-reviewed medical and health-economic literature a MEDLINE-based literature research was conducted in June 2009. Furthermore the web presences of international HTA organisations were screened for relevant publications. Language was limited to English and German. Finally 29 health-economic publications which refer to 26 modelling studies were included in the review. RESULTS: Within the study results there is significant variation due to the heterogeneity of methodical backgrounds and input parameters. Base case results (including direct cost for vaccination of female adolescences screening vs. solely screening) vary from a3,000 to a40,000 per QALY and from a9,000 to a65,000 per LYG. Due to the consideration of herd immunity the application of transmission models frequently resulted in lower cost-effectiveness ratios than static cohort models. Assumptions about the duration of protection can be considered as the major influencing factor within all studies. CONCLUSIONS: Regarding the long-term consequences of HPV vaccination, international studies suggest that HPV vaccination is costeffective when assuming a lifelong protection. Because modelling results significantly depend on the duration of immunization which is associated with a high degree of uncertainty it is not possible to draw a final conclusion regarding the costeffectiveness of HPV vaccination based on the current health-economic evidence. Hence, risk-sharing-agreements between third-party payers and manufacturers would pose an option to balance the consequences of uncertainty towards the duration of protection on cost-effectiveness.
PCN108 PHARMAECONOMIC EVALUATION OF THE USE OF PROLONGED LIBERATION HIDROMORFONE IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN FOR CANCER AT AN INSTITUTIONAL LEVEL IN MEXICO
Vargas J 1 , Tenorio C 2 , Martínez J 3 , Soto-Molina H 4 , Castillejos Zenteno C 4 1 Econopharma, Mexico, Mexico, 2 Instituto Nacional de Cancerología, Mexico, DF, Mexico, 3 Econopharma, México D.F., Mexico, 4 Janssen Cilag, Mexico, Mexico OBJECTIVES: To demonstrate that the use of prolonged liberation hidromorfone (PLHM) in the management of moderate to severe chronic pain for cancer (MCCP) is cost-effective and demonstrates cost-utility compared with prolonged liberation morphine (LM) from the perspective of the Instituto Mexicano del Seguro Social (IMSS). METHODS: A decision tree was built with a one year time horizon and validated by an expert panel (EP) . An assumption in the model is that, if any of the initial treatments fail, fentanil would be used. The effectiveness data (defined as quality of life related to health-QLH) utility (defined in Qalys), and adverse events (AE) of the medications were obtained from the literature with a systematic revision. The total cost was integrated with the cost of medications (average dose required for the sustained efficacy and extended use in a year) and attention of the AE for the use of the opioids, through the EP. The unitary costs were obtained from the IMSS. An incremental analysis of cost and results in health was realized, to compare PLHM and LM. A sensitivity analysis was also accomplished (deterministic and probabilistic) as well as a budgetary impact analysis. RESULTS: Patients with MCCP that used PLHM obtain more QLH (6.06 vs 4.44) and Qalys (0.5620 vs 0.5324) than those that used LM. In addition, patients using PLHM would show less AE than those using lM. PLHM resulted as the alternative with less unitary annual average total cost than LM: $46,242.59 and $50,074.04, respectively. PLHM is a dominant option compared with LM. Sensitivity analysis showed robustness in the results. The budgetary impact shows saving of more than 99 million pesos a year using PLHM instead of LM in the health public institutions. CONCLUSIONS: PLHM is an effective option that can be costsaving in the treatment of MCCP in Mexico.
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COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE DUTCH SETTING
Pompen M 1 , ten Hoor G 1 , Carr E 2 , Aultman R 2 1 Roche Nederland b.v., Woerden, The Netherlands, 2 F. Hoffmann-La Roche, Basel, Switzerland OBJECTIVES: To determine the cost-effectiveness of rituximab (RTX) added to first line chemotherapy in patients with chronic lymphocytic leukemia (CLL) in the Netherlands (NL). Results were used to identify parameters to explore in a local population-based haematological registry (PHAROS). METHODS: A three health state transition cost-effectiveness model was developed to evaluate the costs and clinical outcomes of treatment with either chemotherapy (fludarabine cyclophosphamide; FC) or RTX FC. Patient level data were obtained from the pivotal study CLL-8 (Hallek et al., 2008) . As chlorambucil (C) is frequently used in NL, an indirect comparison of RTX-FC vs. C was included. Patients commenced in the progression-free (PFS) state with transitions to progressive disease or death. PFS and overall survival (OS) data were extrapolated over 15 years with monthly cycles. Utility values originated from a CLL HTA study using the EQ-5D York Tariff. The perspective was societal and direct costs were obtained from official Dutch price sources(Farmacother (Farmacother apeutisch Kompas, Oostenbrink et al. 2004 ). Effects and costs were discounted at . Effects and costs were discounted at 1.5% and 4% p.a. respectively (Dutch pharmaco-economic guidelines). RESULTS: RTX-FC was more effective than FC or C. RTX-FC treatment resulted in 1 QALY and 1.23 life years gained (LYG) vs. FC. With RTX-FC costs being a 16,317 higher, this resulted in ICERs of a16,242/QALY and a13,217/LYG vs. FC. RTX-FC vs. C resulted in 2.14 QALY gain and 2.64 LYG leading to ICERs of a9813/QALY and a7953/LYG. Results were most sensitive to the time horizon and utility values. However, in all cases RTX-FC treatment was cost-effective. OS, resource use and quality of life will be collected prospectively in PHAROS with the aim of confirming these results. CONCLUSIONS: RXT-FC therapy in NL is cost-effective and represents good value for money. Real life data obtained from PHAROS will be used to reevaluate these outcomes in 3-years time.
